Enesi Pharma and BARDA Drive Enter Public-Private Partnership to Develop ImplaVax® Solid Dose Vaccine Delivery Technology Against Influenza

Enesi Pharma | April 15, 2019

Enesi Pharma and BARDA Drive Enter Public-Private Partnership to Develop ImplaVax® Solid Dose Vaccine Delivery Technology Against Influenza
OXFORD, England, April 15, 2019 /PRNewswire/ -- Enesi Pharma ("Enesi"), an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, announces it has entered a public-private partnership with the U.S. Biomedical Advanced Research and Development Authority's (BARDA) DRIVe (Division of Research, Innovation, and Ventures) initiative to develop new vaccines against influenza enabled by Enesi's ImplaVax® device and formulation technology. ImplaVax® is a novel formulation and needle-free device technology that enables solid dose vaccine implants to be delivered quickly under the skin. The aim of this technology is for healthcare providers or individuals themselves to administer the vaccine using this simple, convenient and reusable needle-free device. ImplaVax® also has the potential to generate improved immune responses, along with reduced storage and distribution costs. This new programme aims to provide a cost-effective technological innovation that improves vaccination uptake, coverage, compliance and preparedness and is part of DRIVe's innovative health security technologies portfolio. DRIVe is seeking and funding extremely bold, radical and disruptive innovative solutions that have the ability to transform health security. Relevant projects in this portfolio may create new technologies or leverage existing technologies in an innovative, disruptive way. Under the programme, Enesi will leverage its ImplaVax® platform, combining a protective influenza vaccine with its simple and robust needle-free vaccine delivery system, enhancing the vaccine's efficacy, thermal stability and rapid administration to a target population. ImplaVax® could become a potentially disruptive technology not only for pandemic influenza, but for multiple vaccines, vaccination protocols, infectious diseases and biological threats.

Spotlight

Pharmacy Talks: Farmacia Pellegrini

Related News

Pharmalutions And Movilitas.Cloud Deliver Serialization Solutions for the Asia-Pacific Region

Movilitas | September 11, 2020

Movilitas announced Pharmalutions Pte Ltd as its newest Movilitas.Cloud partner for the Asia-Pacific region. Under the partnership, Pharmalutions provides greater access to compliance-ready solutions with Movilitas.Cloud, a GAMP 5 validated software as a service solution (SaaS), and their all-European-made Serialization & Aggregation technologies dedicated to the pharmaceutical industry in the region. Their comprehensive portfolio enables companies to comply with global regulations while improving operational efficiencies to deliver safer pharmaceuticals to patients.

Read More

ANDA approves Glenmark Pharmaceuticals for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg

Glenmark Pharmaceuticals Inc | October 19, 2020

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV. According to IQVIATM sales data for the 12 month period ending August 2020, the Rapamune® Tablets, 0.5 mg, 1 mg and 2 mg market2 achieved annual sales of approximately $119.7 million*. Glenmark's current portfolio consists of 165 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Read More

PHARMA TECH

Innovation Zed Announce 2022 Launch of InsulCheck DOSE Add-on Technology for Insulin Pens

Zed | November 15, 2021

Innovation Zed, developer of novel diabetes management technologies headquartered at NovaUCD, at University College Dublin, Ireland are delighted to announce today the arrival of the much anticipated InsulCheck DOSE technology that will be coming to market in 2022. "It is with great excitement that we announce the arrival of our InsulCheck DOSE by Innovation Zed. As the third generation product of the InsulCheck family, this technology has been a dream of our company from its very inception and this product is the culmination of over a decade of work to support multiple daily injection (MDI) pen users. We understood the difficult challenges presented by various injection pens and in particular the difficulties in working on a technology to reliably and accurately support low-cost disposable pens. This is the reason we at Innovation Zed took an incremental approach to developing the InsulCheck DOSE product.We have taken a unique approach in developing this technology by working closely with users, caregivers, software developers, medical device specialists and previous generations of InsulCheck products to design and develop a product that bolsters and supports the needs of all stakeholders.'' Dr Dean Minnock, CEO at Innovation Zed Innovation Zed has collaborated with SHL Medical in the development of InsulCheck DOSE. SHL Medical is a world-leading provider of drug delivery solutions and also offers design-to-build and contract manufacturing services for various medical products through its subsidiary, SHL Technologies. What is InsulCheck DOSE? InsulCheck DOSE is a single unit add-on device for pen injectors that automatically captures dose value dialled, injection event time stamp, temperature and mounting/unmounting events. Through Bluetooth® Low Energy (BLE) technology, InsulCheck DOSE transmits these data points to a paired companion software platform in real time for inclusion in diabetes management therapy. "InsulCheck DOSE technology supports MDI users by enhancing their traditional injection pen and transforming it into a smart pen that can optimise their treatment and reduce the stresses caused by MDI therapy. Through this technology we are enabling every MDI user to make their existing injection pen a smart pen without having to compromise or change from their existing HMO or health service provider" - said Dr Minnock. InsulCheck DOSE Features The technology utilises a multi-sensor approach to accurately detect and register the actual dosage dialled and provide an injection event time stamp to log the event. The incorporated temperature sensors constantly monitor the ambient temperature of the area surrounding the injection pen, providing safety notifications to the user if the surrounding temperature may affect the drug housed inside the pen. Using an OLED display, InsulCheck DOSE provides visual information and feedback to the user, helping improve best practice procedures. A rechargeable lithium battery powers the DOSE device and is capable of operating well over 1 week at a time between charges. As a BLE enabled product, all data captured by InsulCheck DOSE is transferred in real time to a paired mobile application. If the user does not wish or is unable to remain connected with a companion software platform, InsulCheck DOSE has built-in memory to store over 40 days' worth of injection history at a time. Through modification of the sleeve component and firmware refinement, InsulCheck DOSE can become applicable to all injection pens for various drug treatments. At launch, it will support a range of reusable and disposable injection pens on the insulin market from Novo Nordisk, Lilly and Sanofi. "Our ability to learn, adapt and improve our technology is one of the key aspects of InsulCheck DOSE and one that separates us greatly from our competitors. The future-proof design of InsulCheck DOSE means that it can be adapted to support the various pen mechanisms in use today, whilst maintaining accuracy and reliability for the patient. Among the numerous unique features of this product is the built in Firmware Over The Air (FOTA) capability which allows continuous optimisation of the device's firmware even when deployed in the field. That future-proofing allows InsulCheck DOSE to adapt to physical injection pen variations from the pen manufacturers and improve on device performance 'on the go' from real world user behaviours" - said Dr Minnock. Value Proposition The InsulCheck DOSE device helps patients, automatically track their daily injection and monitor treatment adherence. The intended use of InsulCheck DOSE is as a supporting component in a management ecosystem for therapy optimisation, remote monitoring and enhanced connected care. Dr Minnock explained, "InsulCheck DOSE is a disruptive technology that will revolutionise an entire market and change the lives of millions of MDI users worldwide. Innovation Zed have entered into discussions with market leaders in the diabetes management sector with the intention of finding a strategic global partner in taking this InsulCheck DOSE technology to the market. InsulCheck DOSE is an attractive offering to any organisation working in this space as it can significantly enhance their existing offering to become more competitive and command new growth and additional market share." Conclusion InsulCheck DOSE enters production at the end of Q2 2022 and will be available as an FDA registered and CE marked product. Manufacturing of InsulCheck DOSE will be handled by Innovation Zed's existing manufacturing partner SHL Technologies, a subsidiary of SHL Medical. If you wish to understand InsulCheck DOSE or any of our technology offerings in greater detail, please feel free to visit our website or reach out to us directly.

Read More

Spotlight

Pharmacy Talks: Farmacia Pellegrini